Page last updated: 2024-12-08
anordiol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
anordiol: RN given refers to (2alpha,5alpha,17alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 164779 |
MeSH ID | M0081053 |
Synonyms (23)
Synonym |
---|
1045-29-0 |
dicyclopenta[a,f]naphthalene-1,7-diol,1,7-diethynylhexadecahydro-8a,10a-dimethyl-, (1r,3as,3br,5as,7r,8as,8bs,10as)- |
dicyclopenta(a,f)naphthalene-1,7-diol, 1,7-diethynylhexadecahydro-8a,10a-dimethyl-, (1r,3as,3br,5as,7r,8as,8bs,10as)- |
a-nor-5-alpha,17-alpha-pregn-20-yne-2-beta,17-diol, 2-ethynyl- |
af 45 (pharmaceutical) |
dicyclopenta(a,f)naphthalene-1,7-diol, 1,7-diethynylhexadecahydro-8a,10a-dimethyl-, (1r-(1alpha,3abeta,3balpha,5abeta,7alpha,8aalpha,8bbeta,10aalpha))- |
a-norpregn-20-yne-2,17-diol, 2-ethynyl-, (2-beta,5-alpha,17-alpha)- |
h 241 |
anordiol |
H241 , |
af 45 |
af-45 |
(2r,3as,3bs,5as,6r,8as,8br,10as)-2,6-diethynyl-3a,5a-dimethyl-1,3,3b,4,5,7,8,8a,8b,9,10,10a-dodecahydroindeno[5,4-e]indene-2,6-diol |
unii-5g6h10z92j |
5g6h10z92j , |
RC90507000 , |
2-ethynyl-a-nor-17-alpha-pregn-20-yne-2-beta,17-diol |
niosh/rc9050700 |
a-nor-17-alpha-pregn-20-yne-2-beta,17-diol, 2-ethynyl- |
h-241 |
Q27262091 |
DTXSID60909005 |
AKOS040745564 |
Research Excerpts
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"Anordiol and estradiol treatments significantly increased ovarian and uterine weight and serum LH concentrations, but CC and TA had no effect on these parameters." | ( Effect of anordiol on ovarian hormone secretion, ovulation, and uterine and vaginal responses in the immature rat. Chatterton, RT; Lu, YC, 1994) | 1.41 |
Compound-Compound Interactions
The pregnancy termination potency of mifepristone, onapristone and ORG 3806--alone and in combination with the estrogenic/antiestrogenic compound anordiol--was evaluated.
Excerpt | Reference | Relevance |
---|---|---|
"In view of the unexpected ability of anordrin to synergize with RU 486 in terminating pregnancy, it was pertinent to examine the actions of the dihydroxylated metabolite of anordrin, anordiol, alone and in combination with RU 486." | ( Anordiol is more potent than anordrin for terminating pregnancy when administered with RU 486. Bardin, CW; Chang, CC; Wang, WC, 1993) | 1.92 |
"The effectiveness of mifepristone, onapristone, and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated." | ( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat. Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997) | 0.74 |
"The pregnancy termination potency of varying doses of mifepristone, onapristone, and ORG 3806--alone and in combination with the estrogenic/antiestrogenic compound anordiol--was evaluated in adult rats." | ( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat. Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (18.18) | 18.7374 |
1990's | 15 (68.18) | 18.2507 |
2000's | 2 (9.09) | 29.6817 |
2010's | 1 (4.55) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 23 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |